Metformin in obesity, cancer and aging: addressing controversies
Language: 
English
Short Title: 
Metformin in obesity, cancer and aging
Abstract: 

Metformin, an oral anti-diabetic drug, is being considered increasingly for treatment and prevention of cancer, obesity as well as for the extension of healthy lifespan. Gradually accumulating discrepancies about its effect on cancer and obesity can be explained by the shortage of randomized clinical trials, differences between control groups (reference points), gender- and age-associated effects and pharmacogenetic factors. Studies of the potential antiaging effects of antidiabetic biguanides, such as metformin, are still experimental for obvious reasons and their results are currently ambiguous. Here we discuss whether the discrepancies in different studies are merely methodological or inherently related to individual differences in responsiveness to the drug.

Author(s): 
Berstein, Lev M.
Item Type: 
Journal Article
Publication Title: 
Aging
Journal Abbreviation: 
Aging (Albany NY)
Publication Date: 
2012-05
Publication Year: 
2012
Pages: 
320-329
Volume: 
4
Issue: 
5
ISSN: 
1945-4589
Library Catalog: 
NCBI Published Medical (?)
Extra: 
PMID: 22589237 PMCID: PMC3384433

Turabian/Chicago Citation

Lev M. Berstein. 2012-05. "Metformin in obesity, cancer and aging: addressing controversies." Aging 4: 5: 320-329.

Wikipedia Citation

<ref> {{Cite journal | doi = | issn = 1945-4589 | volume = 4 | pages = 320-329 | last = Berstein | first = Lev M. | coauthors = | title = Metformin in obesity, cancer and aging: addressing controversies | journal = Aging | date = 2012-05 | pmid = | pmc = }} </ref>